Oxlumo

Active Ingredient(s): Lumasiran
FDA Approved: * November 23, 2020
Pharm Company: * ALNYLAM PHARMS INC
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Oxlumo Overview

Lumasiran, sold under the brand name Oxlumo, is a medication for the treatment of primary hyperoxaluria type 1 (PH1).[4][2][5] The most common side effects include injection site reactions and abdominal pain.[2] Lumasiran is a double-stranded small interfering ribonucleic acid (siRNA) that reduces levels of glycolate oxidase (GO) enzyme by targeting the HAO1 messenger ribonucleic acid (mRNA) in hepatocytes through RNA interferenc...

Read more Oxlumo Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Lumasiran

Recent Oxlumo Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Lumasiran
  • Solution: 94.5mg/0.5ml, 94.5mg/0.5ml (94.5mg/0.5ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Lumasiran or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 10 April 2021.

We are committed to your privacy.

Copyright © 2005-2021 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA